LifeMD's fair value estimate has been trimmed from roughly $10.63 to $9.25 per share as analysts digest softer Q3 results and a reset 2025 outlook. A slightly higher discount rate, now about 8.26% versus 8.23%, reflects elevated perceived risk around execution in weight management and near term revenue trends. Stay tuned to see how you can track these evolving assumptions and keep up with the shifting narrative around LifeMD's valuation.

Stay updated as the Fair Value for LifeMD shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on LifeMD.

???? Bullish Takeaways

Despite cutting targets, H.C. Wainwright (Yi Chen) and Lake Street (Ryan Meyers) both reiterate Buy ratings, signaling that they still see upside from current levels even after lowering their price objectives to $9 (from $13) and $8 (from $14), respectively.

Several firms emphasize that LifeMD remains a focused telehealth and pharmacy platform following the WorkSimpli divestiture. They view this as sharpening execution on the core business and supporting the longer term valuation case.

Lake Street describes Q3 as showing ongoing operational progress, and BTIG expects current headwinds and revenue lumpiness to be temporary. They argue that growth could reaccelerate in 2026 and help justify a higher medium term valuation, even after its target cut to $10 from $18.

BTIG highlights LifeMD's adherence to regulatory and quality protocols in weight management relative to lower cost compounded GLP 1 competitors. They suggest that disciplined execution and brand positioning could support pricing power and margin resilience over time.

???? Bearish Takeaways

Mizuho (Steven Valiquette) lowers its target to $6 from $8 and maintains a Neutral rating, underscoring more cautious sentiment around Q3 revenue and EBITDA misses and the risk that near term results may not support a higher valuation multiple.

All four firms reduce price targets, reflecting a reassessment of growth and profitability assumptions as competitive pressure in virtual weight management intensifies, particularly from lower priced compounded GLP 1 offerings that are weighing on LifeMD's near term revenue trajectory.

Analysts at Mizuho, Lake Street, and BTIG collectively flag competitive pressures and revised guidance for the standalone telehealth business as key risks. They suggest that execution will need to improve and growth visibility strengthen before the market is willing to assign richer valuation multiples again.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Issued new guidance for Q4 2025 revenue of $45M to $46M and full year 2025 revenue of $192M to $193M, implying about 24% year over year growth versus 2024 and reinforcing management's confidence in the medium term trajectory.

Disclosed it will be unable to file its next Form 10 Q with the SEC by the required deadline, raising questions about internal processes and adding near term uncertainty around financial reporting.

Expanded its collaboration with Novo Nordisk to offer Ozempic (semaglutide) to eligible patients at $499 per month through an integrated NovoCare pharmacy pathway, aiming to strengthen LifeMD's position in the weight management market.

Broadened affiliated pharmacy capabilities to include advanced non sterile compounding for oral and topical medications, increasing vertical integration and reducing dependence on third party pharmacies to support margins and service reliability.

Fair Value: Reduced from approximately $10.63 to $9.25 per share, reflecting a modest downward revision in the equity valuation.

Discount Rate: Increased slightly from about 8.23% to 8.26%, implying a marginally higher required return and risk perception.

Revenue Growth: Shifted materially from a projected increase of roughly +4.1% to a decline of about −1.3%, indicating a significantly weaker top line outlook.

Net Profit Margin: Raised from an estimated 5.1% to roughly 7.1%, signaling improved expectations for profitability and operating efficiency.

Future P/E: Lowered from around 49.9× to 39.8×, pointing to a notable compression in the valuation multiple applied to forward earnings.

Narratives on Simply Wall St turn raw numbers into a living story, connecting a company’s strategy and risks to explicit forecasts for revenue, earnings, and margins that roll up into a Fair Value. Hosted on the Community page used by millions of investors, Narratives make it easy to compare Fair Value to today’s share price, decide when to buy or sell, and automatically update as fresh news, filings, and earnings reshape the outlook.

Head over to the Simply Wall St Community and follow the Narrative on LifeMD to stay on top of:

How expansion into new care domains, from behavioral health to women’s health, supports long term growth and diversifies revenue away from weight management.

Whether AI driven efficiencies and subscription based models can offset rising competition, refund rates, and customer acquisition costs.

How updated forecasts for revenue growth, margins, and a future PE of 39.8x translate into a fair value of $9.25 versus today’s market price.

Read the full original narrative on LifeMD here: LFMD: Weight Management Headwinds Will Set Up Margin Expansion And Rebound Potential.

Curious how numbers become stories that shape markets? Explore Community Narratives

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include LFMD.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com